Oxurion N.V.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TBGNF research report →
Companywww.oxurion.com
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME.
- CEO
- Thomas Graney
- IPO
- 2007
- Employees
- 27
- HQ
- Leuven, BE
Price Chart
Valuation
- Market Cap
- $433.72M
- P/E
- 0.02
- P/S
- 126.18
- P/B
- -0.00
- EV/EBITDA
- 5.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -4050.00%
- Op Margin
- -138200.00%
- Net Margin
- 97950.00%
- ROE
- -17.00%
- ROIC
- 264.73%
Growth & Income
- Revenue
- $3.00K · -98.86%
- Net Income
- $119.00K · 100.63%
- EPS
- $0.09 · 100.08%
- Op Income
- $382.00K
- FCF YoY
- 78.82%
Performance & Tape
- 52W High
- $2.00
- 52W Low
- $0.17
- 50D MA
- $0.17
- 200D MA
- $0.18
- Beta
- 0.35
- Avg Volume
- 0
Get TickerSpark's AI analysis on TBGNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TBGNF Coverage
We haven't published any research on TBGNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TBGNF Report →